Glial Cells in ALS: The Missing Link?

Physical Medicine and Rehabilitation Clinics of North America

Volumn 19, Issue 3, 2008, Pages 441-459

  Raibon, Elsa ^a   Todd, Lisa Marie ^b   Möller, Thomas ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CILIARY NEUROTROPHIC FACTOR; CYCLOSPORIN A; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASE INHIBITOR; MINOCYCLINE; PLACEBO; PREDNISOLONE; RILUZOLE; SODIUM PHENYLBUTYRATE; TACROLIMUS; THALIDOMIDE; TRICHOSTATIN A; UBIDECARENONE; VALPROIC ACID; VASCULOTROPIN; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; CAUSE OF DEATH; CELL FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DISEASE DURATION; GLIA CELL; HUMAN; MICROGLIA; MOTOR NEURON DISEASE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; NEUROGLIA; NEUROPROTECTIVE AGENTS;

EID: 46749125729     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2008.04.003     Document Type: Review

References (141)

1. Rowland L.P. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 58 3 (2001) 512-515
2. Brown R.H., Meininger V., and Swash M. Amyotrophic lateral sclerosis. In: Brown R.H., Meininger V., and Swash M. (Eds). Amyotrophic lateral sclerosis (2000), Martin Dunitz, London p. 3-31
3. Bruijn L.I., Miller T.M., and Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27 (2004) 723-749
4. Strong M., and Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4 3 (2003) 136-143
5. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2 11 (2001) 806-819
6. Ludolph A.C., Meyer T., and Riepe M.W. The role of excitotoxicity in ALS-what is the evidence?. J Neurol 247 Suppl 1 (2000) I7-16
7. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J Neurol 247 Suppl 1 (2000) I1-I6
8. Shaw P.J., and Eggett C.J. Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J Neurol 247 Suppl 1 (2000) I17-I27
9. Weydt P., and Möller T. Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. Neuroreport 16 6 (2005) 527-531
10. Eisen A.A. Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve 18 7 (1995) 741-752
11. Strong M.J., Kesavapany S., and Pant H.C. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J Neuropathol Exp Neurol 64 8 (2005) 649-664
12. Dhib-Jalbut S., Arnold D.L., Cleveland D.W., et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 176 1-2 (2006) 198-215
13. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19 8 (1996) 312-318
14. Streit W.J. Microglial senescence: does the brain's immune system have an expiration date?. Trends Neurosci 29 9 (2006) 506-510
15. Streit W.J., Walter S.A., and Pennell N.A. Reactive microgliosis. Prog Neurobiol 57 6 (1999) 563-581
16. McGeer E.G., and McGeer P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 5 10 (1999) 821-836
17. In: Hanisch U.K., Kohsaka S., and Möller T. (Eds). Special Issue Microglia (2002), Glia ;40(2):131-3
18. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40 2 (2002) 133-139
19. Nimmerjahn A., Kirchhoff F., and Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308 5726 (2005) 1314-1318
20. Hanisch U.K. Microglia as a source and target of cytokines activities in the brain. In: Streit W.J. (Ed). Microglia in the degenerating and regenerating CNS (2001), Springer Verlag, New York p. 79-125
21. Wyss-Coray T., and Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35 5 (2002) 419-432
22. Brown A.M., and Ransom B.R. Astrocyte glycogen and brain energy metabolism. Glia 55 12 (2007) 1263-1271
23. Abbott N.J., Ronnback L., and Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7 1 (2006) 41-53
24. Haydon P.G., and Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 86 3 (2006) 1009-1031
25. Montana V., Malarkey E.B., Verderio C., et al. Vesicular transmitter release from astrocytes. Glia 54 7 (2006) 700-715
26. Sattler R., and Rothstein J.D. Regulation and dysregulation of glutamate transporters. Handb Exp Pharmacol 175 (2006) 277-303
27. Dong Y., and Benveniste E.N. Immune function of astrocytes. Glia 36 2 (2001) 180-90
28. Farina C., Aloisi F., and Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 28 3 (2007) 138-145
29. Tilleux S., and Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 85 10 (2007) 2059-2070
30. de Haas A.H., van Weering H.R., de Jong E.K., et al. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 36 2 (2007) 137-151
31. Ince P.G., Shaw P.J., Slade J.Y., et al. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol (Berl) 92 4 (1996) 395-403
32. Kawamata T., Akiyama H., Yamada T., et al. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140 3 (1992) 691-707
33. Ince P.G. Neuropathology of ALS. In: Brown R.H., Meininger V., and Swash M. (Eds). Amyotrophic lateral sclerosis (2000), Martin Dunitz, London 83-112
34. Turner M.R., Cagnin A., Turkheimer F.E., et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15 3 (2004) 601-609
35. Alexianu M.E., Kozovska M., and Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57 7 (2001) 1282-1289
36. Hall E.D., Oostveen J.A., and Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23 3 (1998) 249-256
37. Olsen M.K., Roberds S.L., Ellerbrock B.R., et al. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol 50 6 (2001) 730-740
38. Yoshihara T., Ishigaki S., Yamamoto M., et al. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80 1 (2002) 158-167
39. Elliott J.L. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 95 1-2 (2001) 172-178
40. Nguyen M.D., Julien J.P., and Rivest S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann Neurol 50 5 (2001) 630-639
41. Hensley K., Floyd R.A., Gordon B., et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82 2 (2002) 365-374
42. Almer G., Guegan C., Teismann P., et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 49 (2001) 176-185
43. Chen L.C., Smith A., Ben Y., et al. Temporal gene expression patterns in G93A/SOD1 mouse. Amyotroph Lateral Scler Other Motor Neuron Disord 5 3 (2004) 164-171
44. Xie Y., Weydt P., Howland D.S., et al. Expression of neuroinflammatory mediators and growth factors in the spinal cord of the G93A SOD1 transgenic rats. Neuroreport 15 16 (2004) 2513-2516
45. Moreau C., Devos D., Brunaud-Danel V., et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?. Neurology 65 12 (2005) 1958-1960
46. Dengler R., von Neuhoff N., Bufler J., et al. Amyotrophic lateral sclerosis: new developments in diagnostic markers. Neurodegener Dis 2 3-4 (2005) 177-184
47. Raoul C., Estevez A.G., Nishimune H., et al. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 35 6 (2002) 1067-1083
48. Figlewicz D.A., Dong L., Mlodzienski M., et al. Culture models of neurodegenerative disease. Ann N Y Acad Sci 919 (2000) 106-118
49. Wen W., Sanelli T., Ge W., et al. Activated microglial supernatant induced motor neuron cytotoxicity is associated with upregulation of the TNFR1 receptor. Neurosci Res 55 1 (2006) 87-95
50. Engelhardt J.I., Tajti J., and Appel S.H. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 50 1 (1993) 30-36
51. Holmoy T. T cells in amyotrophic lateral sclerosis. Eur J Neurol 15 4 (2008) 360-366
52. Villoslada P., and Genain C.P. Role of nerve growth factor and other trophic factors in brain inflammation. Prog Brain Res 146 (2004) 403
53. Beck M., Karch C., Wiese S., et al. Motoneuron cell death and neurotrophic factors: basic models for development of new therapeutic strategies in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2 Suppl 1 (2001) S55-S68
54. Oosthuyse B., Moons L., Storkebaum E., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28 2 (2001) 131-138
55. Markus A., Patel T.D., and Snider W.D. Neurotrophic factors and axonal growth. Curr Opin Neurobiol 12 5 (2002) 523-531
56. Lambrechts D., Storkebaum E., and Carmeliet P. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?. Trends Mol Med 10 6 (2004) 275-282
57. Greenberg D.A., and Jin K. VEGF and ALS: the luckiest growth factor?. Trends Mol Med 10 1 (2004) 1-3
58. Clement A.M., Nguyen M.D., Roberts E.A., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 5642 (2003) 113-117
59. Boillee S., Yamanaka K., Lobsiger C.S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 5778 (2006) 1389-1392
60. Beers D.R., Henkel J.S., Xiao Q., et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 103 43 (2006) 16021-16026
61. Weydt P., Yuen E.C., Ransom B.R., et al. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 48 2 (2004) 179-182
62. Xiao Q., Zhao W., Beers D.R., et al. Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem 102 6 (2007) 2008-2019
63. Urushitani M., Sik A., Sakurai T., et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 9 1 (2006) 108-118
64. Knott A.B., and Bossy-Wetzel E. ALS: astrocytes take center stage, but must they share the spotlight?. Cell Death Differ 14 12 (2007) 1985-1988
65. Holden C. Neuroscience. Astrocytes secrete substance that kills motor neurons in ALS. Science 316 5823 (2007) 353
66. Julien J.P. ALS: astrocytes move in as deadly neighbors. Nat Neurosci 10 5 (2007) 535-537
67. Rothstein J.D. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci 3 6 (1995) 348-359
68. Van Den Bosch L., Van Damme P., Bogaert E., et al. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762 11-12 (2006) 1068-1082
69. Nagai M., Re D.B., Nagata T., et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10 5 (2007) 615-622
70. Als-Tdf. Treatment master list. Available at:. http://www.als.net/research/treatments/treatmentList.asp Accessed 2006
71. Turner M.R., Parton M.J., and Leigh P.N. Clinical trials in ALS: an overview. Semin Neurol 21 2 (2001) 167-175
72. Carri M.T., Grignaschi G., and Bendotti C. Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 27 5 (2006) 267-273
73. Traynor B.J., Bruijn L., Conwit R., et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67 1 (2006) 20-27
74. Miller R.G., Mitchell J.D., Lyon M., et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 4 3 (2003) 191-206
75. McGeer P.L., and McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26 4 (2002) 459-470
76. Jankowsky J.L., Savonenko A., Schilling G., et al. Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr Neurol Neurosci Rep 2 5 (2002) 457-464
77. Julien J.P., and Kriz J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762 11-12 (2006) 1013-1024
78. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26 (2007) 1
79. Rothstein J.D. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol 53 4 (2003) 423-426
80. Weydt P., Weiss M.D., Moller T., et al. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Investig Drugs 3 12 (2002) 1720-1724
81. Dimayuga F.O., Wang C., Clark J.M., et al. SOD1 overexpression alters ROS production and reduces neurotoxic inflammatory signaling in microglial cells. J Neuroimmunol 182 1-2 (2007) 89-99
82. Rocca B., and FitzGerald G.A. Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol 2 5 (2002) 603-630
83. FitzGerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2 11 (2003) 879-890
84. Kaufmann W.E., Worley P.F., Pegg J., et al. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A 93 6 (1996) 2317-2321
85. Consilvio C., Vincent A.M., and Feldman E.L. Neuroinflammation, COX-2, and ALS-a dual role?. Exp Neurol 187 1 (2004) 1-10
86. Engblom D., Ek M., Saha S., et al. Prostaglandins as inflammatory messengers across the blood-brain barrier. J Mol Med 80 1 (2002) 5-15
87. Takadera T., Yumoto H., Tozuka Y., et al. Prostaglandin E(2) induces caspase-dependent apoptosis in rat cortical cells. Neurosci Lett 317 2 (2002) 61-64
88. Wang T., Qin L., Liu B., et al. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem 88 4 (2004) 939-947
89. Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand 108 2 (2003) 125-129
90. Almer G., Teismann P., Stevic Z., et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 58 8 (2002) 1277-1279
91. Yokota O., Terada S., Ishizu H., et al. Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia. Acta Neuropathol 107 5 (2004) 399-405
92. Yasojima K., Tourtellotte W.W., McGeer E.G., et al. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 57 6 (2001) 952-956
93. Drachman D.B., Frank K., Dykes-Hoberg M., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52 6 (2002) 771-778
94. Pompl P.N., Ho L., Bianchi M., et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 17 6 (2003) 725-727
95. Klivenyi P., Gardian G., Calingasan N.Y., et al. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci 21 3 (2003) 191-198
96. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60 1 (2006) 22-31
97. Yrjanheikki J., Keinanen R., Pellikka M., et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95 26 (1998) 15769-15774
98. Yrjanheikki J., Tikka T., Keinanen R., et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96 23 (1999) 13496-13500
99. Teng Y.D., Choi H., Onario R.C., et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 101 9 (2004) 3071-3076
100. Tikka T., Fiebich B.L., Goldsteins G., et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21 8 (2001) 2580-2588
101. Tikka T.M., and Koistinaho J.E. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166 12 (2001) 7527-7533
102. Wu D.C., Jackson-Lewis V., Vila M., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22 5 (2002) 1763-1771
103. Kriz J., Nguyen M.D., and Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10 3 (2002) 268-278
104. Van Den Bosch L., Tilkin P., Lemmens G., et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13 8 (2002) 1067-1070
105. Zhu S., Stavrovskaya I.G., Drozda M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 6884 (2002) 74-78
106. Gordon P.H., Moore D.H., Gelinas D.F., et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62 10 (2004) 1845-1847
107. Pontieri F.E., Ricci A., Pellicano C., et al. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol Sci 26 4 (2005) 285-287
108. Butler R., and Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7 10 (2006) 784-796
109. Saha R.N., and Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 13 4 (2006) 539-550
110. Ryu H., Smith K., Camelo S.I., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93 5 (2005) 1087-1098
111. Tremolizzo L., Rodriguez-Menendez V., Sala G., et al. Valproate and HDAC inhibition: a new epigenetic strategy to mitigate phenotypic severity in ALS?. Amyotroph Lateral Scler Other Motor Neuron Disord 6 3 (2005) 185-186
112. Blanchard F., and Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today 10 3 (2005) 197-204
113. Kelly W.K., O'Connor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 17 (2005) 3923-3931
114. Adcock I.M. Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig Drugs 7 11 (2006) 966-973
115. Leoni F., Zaliani A., Bertolini G., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 99 5 (2002) 2995-3000
116. Franks M.E., Macpherson G.R., and Figg W.D. Thalidomide. Lancet 363 9423 (2004) 1802-1811
117. Teo S.K., Stirling D.I., and Zeldis J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 10 2 (2005) 107-114
118. Kiaei M., Petri S., Kipiani K., et al. Thalidomide and Lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26 9 (2006) 2467-2473
119. ALS-TDI. ALS TDI Animal Studies: CoQ10 I. 2003. Available at: http://www.als.net/research/studies/animalStudyDetail.asp?studyType=internal&studyID=44.
120. ALS-TDI. ALS TDI Animals studies: Prednisolone I. 2003. Available at: http://www.als.net/research/studies/animalStudyDetail.asp?studyType=internal&studyID=170.
121. Werdelin L., Boysen G., Jensen T.S., et al. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 82 (1990) 132
122. ALS-TDI. ALS TDI Animals studies: Minocycline I II III. 2003. Available at: http://www.als.net/research/treatments/treatmentDetail.asp?studyType=all&treatmentId=459.
123. Diguet E., Gross C.E., Tison F., et al. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol 189 (2004) 1
124. Zhang W., Narayanan M., and Friedlander R.M. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53 (2003) 267
125. Gordon P.H., Moore D.H., Miller R.G., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6 (2007) 1045
126. ALS-TDI. ALS TDI Animals studies: Thalidomide I-IV. 2001-2005. Available at: http://www.als.net/research/treatments/treatmentDetail.asp?studyType=internal&treatmentId=707.
127. ALS-TDI. ALS TDI Animal Studies: Celebrex I-III. 2001-2005. Available at: http://www.als.net/research/treatments/treatmentDetail.asp?studyType=internal&treatmentId=137.
128. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46 (1996) 1244
129. Aebischer P., Schluep M., Deglon N., et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 2 (1996) 696
130. Suzuki M., McHugh J., Tork C., et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2 (2007) e689
131. Li W., Brakefield D., Pan Y., et al. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp Neurol 203 (2007) 457
132. Azzouz M., Ralph G.S., Storkebaum E., et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413
133. Zheng C., Skold M.K., Li J., et al. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem Biophys Res Commun 363 (2007) 989
134. Storkebaum E., Lambrechts D., Dewerchin M., et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8 (2005) 85
135. Karlsson J., Fong K.S., Hansson M.J., et al. Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neurosurg 101 (2004) 128
136. Kirkinezos I.G., Hernandez D., Bradley W.G., et al. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neurochem 88 (2004) 821
137. Appel S.H., Stewart S.S., Appel V., et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 45 (1988) 381
138. Anneser J.M., Gmerek A., Gerkrath J., et al. Immunosuppressant FK506 does not exert beneficial effects in symptomatic G93A superoxide dismutase-1 transgenic mice. Neuroreport 12 (2001) 2663
139. ALS-TDI. ALS TDI Animals studies: Sodium Valproate I. 2001. Available at: http://www.als.net/research/studies/animalStudyDetail.asp?studyType=internal&studyID=215.
140. UMC Utrecht Clinical Trials Phase III. Sodium Valproate. 2005. Available at: http://www.als.net/research/studies/currentClinicalTrialDetail.asp?studyID=18.
141. ALS-TDI. ALS TDI Animals studies: Trichostatin A I. 2002. Available at: http://www.als.net/research/studies/animalStudyDetail.asp?studyType=internal&studyID=238.